IDEAYA BIOSCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.16 USD | -1.74% |
|
+3.59% | +9.53% |
Financials (USD)
| Sales 2024 * | 19.11M | Sales 2025 * | 97.66M | Capitalization | 2.98B |
|---|---|---|---|---|---|
| Net income 2024 * | -165M | Net income 2025 * | -126M | EV / Sales 2024 * | 124 x |
| Net cash position 2024 * | 618M | Net cash position 2025 * | 514M | EV / Sales 2025 * | 25.2 x |
| P/E ratio 2024 * |
-18
x | P/E ratio 2025 * |
-23.5
x | Employees | 124 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.02% |
More Fundamentals
* Assessed data
More news
Latest transcript on IDEAYA Biosciences, Inc.
More recommendations
More press releases
| 1 day | -4.65% | ||
| 1 week | +1.38% | ||
| Current month | -13.08% | ||
| 1 month | -9.86% | ||
| 3 months | -10.26% | ||
| 6 months | +46.41% | ||
| Current year | +7.20% |
1 week
36.58
40.31
1 month
36.5844.25
Current year
33.4647.74
1 year
18.0947.74
3 years
8.1447.74
5 years
2.9547.74
10 years
2.9547.74
| Managers | Title | Age | Since |
|---|---|---|---|
Yujiro Hata
FOU | Founder | 49 | 15-05-31 |
Andres Briseno
DFI | Director of Finance/CFO | 38 | 16-07-31 |
Michael White
CTO | Chief Tech/Sci/R&D Officer | - | 21-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Terry Rosen
BRD | Director/Board Member | 64 | 16-05-05 |
Wendy Yarno
BRD | Director/Board Member | 68 | 19-12-16 |
Catherine Mackey
BRD | Director/Board Member | 68 | 22-04-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.24% | 2 M€ | -.--% | ||
| 0.09% | 7 M€ | -.--% | - | |
| 0.07% | 0 M€ | 0.00% | - | |
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 38.95 | -2.26% | 343 463 |
| 24-04-24 | 39.85 | +2.13% | 1,369,718 |
| 24-04-23 | 39.02 | +3.80% | 486,221 |
| 24-04-22 | 37.59 | +1.24% | 784,204 |
| 24-04-19 | 37.13 | -1.30% | 726,233 |
Delayed Quote Nasdaq, April 25, 2024 at 11:18 am EDT
More quotes
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
39.85
USD
Average target price
53.5
USD
Spread / Average Target
+34.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.20% | 2.98B | |
| +0.75% | 43.84B | |
| +4.64% | 41.68B | |
| +45.43% | 41.25B | |
| -11.96% | 27.04B | |
| +5.56% | 25.53B | |
| -25.35% | 18.18B | |
| -3.96% | 12.29B | |
| +25.30% | 12.29B | |
| +7.21% | 11.15B |
- Stock Market
- Equities
- IDYA Stock
